Syngene concludes acquisition of biologics manufacturing facility from Stelis Biopharma
Bangalore: Syngene International has announced the conclusion of the acquisition of a multi-modal biologics manufacturing facility from Stelis Biopharma Ltd as announced on 4 July 2023. The acquisition of the ‘Unit 3’ biologics manufacturing facility was concluded at a revised gross value of Rs 617 crores adjusted from the earlier gross value of Rs 702 crores. The reduction in gross value reflects the retention of certain equipment not currently installed in the facility by Stelis Biopharma Ltd.
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene. It also includes a commercial scale, high speed, fill-finish unit – an essential capability for drug product manufacturing. The Unit has been acquired effective 1st December 2023 on payment of Rs 395 crores. The balance, subject to final adjustments, will be paid in December 2023 on completion of certain post-closing actions by Stelis Biopharma Ltd.
Read also: Evaluate safety in proposed study: CDSCO Panel tells Syngene on Suplatast Tosilate Capsule
Read also: Syngene International reports 14.22 percent increase in net profit at Rs 116.5 crore in Q2
